Vera Therapeutics (VERA) PT Raised to $25 at JPMorgan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts VERA Hot Sheet
Price: $30.71 +1.52%
Rating Summary:
13 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Rating Summary:
13 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Join SI Premium – FREE
JPMorgan analyst Anupam Rama raised the price target on Vera Therapeutics (NASDAQ: VERA) to $25.00 (from $22.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Hybe Corporation (352820:KS) PT Lowered to KRW290,000 at Goldman Sachs
- Ideaya Biosciences (IDYA) PT Lowered to $57 at Truist Securities
- Dhoot Transmission (DHOOTTRA:IN) PT Raised to INR1,750 at Jefferies
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
